Clinical Trial

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

Study acronym: Eluminate-3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Trial Details
NCT Number NCT07664553
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus
Enrollment 600 participants
Start Date 2026-07-06
Primary Completion 2028-05-23 (estimated)
Study Completion 2028-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-06-24